MARATTO

preprint · SSRN Electronic Journal

Bedaquiline, Delamanid, Linezolid and Clofazimine for the Treatment of Rifampicin- and Fluoroquinolone-Resistant Tuberculosis (endTB-Q): A Phase 3, Open-Label, Multicentre, Randomised, Controlled, Stratified, Non-Inferiority Trial

20251 citationOpen accessUniversity Of Global Health Equity

In plain language

No abstract is available for this record, so no summary has been generated.

Research topics

  • Tuberculosis Research and Epidemiology
  • Mycobacterium research and diagnosis

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.2139/ssrn.5199136

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.